LILRB2: A Potential Drug Target and Biomarker for Leukemia (G10288)

Target Name: LILRB2

NCBI ID: G10288

LILRB2

LILRB2: A Potential Drug Target and Biomarker for Leukemia

Leukemia is a type of cancer that affects the bone marrow and blood cells. It is a serious and life-threatening disease that can be treated with various drugs, but current treatments often have side effects and a low response rate. As a result, there is a need for new and better treatments to treat leukemia.

One potential drug target for leukemia is LILRB2, which is a protein that is expressed in the immune system. LILRB2 plays a critical role in the immune response and has been shown to be involved in the development and progression of many types of cancer, including leukemia.

Research has shown that LILRB2 is involved in the development of leukemia by regulating the activity of T cells, which are a type of immune cell that help to fight off infections and cancer. T cells are able to recognize and destroy cancer cells, but they can also become rogue and continue to divide and spread the cancer. LILRB2 helps to regulate this process and prevent the development of rogue T cells.

Another mechanism by which LILRB2 may contribute to the development of leukemia is by regulating the production of blood cells. Leukemia is a disease that is characterized by the uncontrolled production of white blood cells, which are responsible for fighting off infections and cancer. LILRB2 helps to regulate the production of these cells and can also contribute to the development of leukemia by promoting the production of abnormal cells.

In addition to its role in the immune response and the production of blood cells, LILRB2 may also be involved in the development of leukemia by regulating the signaling processes that occur within cells. For example, LILRB2 has been shown to interact with the protein PD-L1, which is a protein that is expressed in many types of cancer cells. When PD-L1 is expressed, it can suppress the immune response and contribute to the development of cancer. LILRB2 may help to prevent this from happening by regulating the signaling processes that occur between PD-L1 and the immune system.

As a potential drug target, LILRB2 is an attractive target for researchers because it is involved in the immune response and has been shown to be involved in the development and progression of many types of cancer. Additionally, because LILRB2 is a protein that is expressed in the immune system, it is possible that targeting LILRB2 may be less harmful to non-cancer cells than targeting other proteins that are not as tightly regulated by the immune system.

In addition to its potential as a drug target, LILRB2 may also be used as a biomarker for the diagnosis and prognosis of leukemia. Leukemia can be a difficult disease to diagnose, as the symptoms and signs of the disease can be similar to those of many other conditions. Additionally, the prognosis for leukemia is often poor, with many patients experiencing a relapse of the disease within a few years of diagnosis.

Research has shown that LILRB2 can be used as a biomarker for the diagnosis and prognosis of leukemia by measuring the level of LILRB2 in the blood. Studies have shown that higher levels of LILRB2 in the blood are associated with a more favorable prognosis for patients with leukemia. This suggests that LILRB2 may be a useful biomarker for the diagnosis and prognosis of leukemia.

In conclusion, LILRB2 is a protein that is expressed in the immune system and has been shown to be involved in the development and progression of many types of cancer, including leukemia. As a potential drug target and biomarker, LILRB2 is an attractive target for researchers because it is involved in the immune response and has been shown to be involved in the development and progression of many types of cancer. Additionally, because LILRB2 is a protein that is expressed in the immune system, it is possible that targeting LILRB2 may be less harmful to non-cancer cells than targeting other proteins that are not as tightly regulated by the immune system. Further research is needed to fully understand the role of LILRB2 in the development and treatment of leukemia.

Protein Name: Leukocyte Immunoglobulin Like Receptor B2

Functions: Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed:11169396, PubMed:12853576, PubMed:16455647, PubMed:20448110, PubMed:27859042). Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:20448110, PubMed:27859042, PubMed:16455647). Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11875462, PubMed:12853576, PubMed:9548455, PubMed:9842885)

The "LILRB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LILRB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets